Targeting AML Resistance with Two Novel Combinations Demonstrate Superior Efficacy in TP53, HLA-B, MUC4 and FLT3 mutations
Elham Gholizadeh, Ehsan Zangene, Alun Parsons…·Mohieddin Jafari
This study evaluates two drug combinations for AML treatment, showing improved efficacy over venetoclax-based therapy in specific mutation profiles.